Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment

Molecular Imaging and Biology

Volumn 10, Issue 6, 2008, Pages 349-355

  Graf, Nicolas ^a   Herrmann, Ken ^a   den Hollander, Jürgen ^a   Fend, Falko ^b   Schuster, Tibor ^c   Wester, Hans Jürgen ^a   Senekowitsch Schmidtke, Reingard ^a   Büschenfelde, Christian Meyer Zum ^a   Peschel, Christian ^a   Schwaiger, Markus ^a   Dechow, Tobias ^a   Buck, Andreas K ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Lymphoma; Nucleosides; Positron emission tomography; Proliferation; Therapy control

Indexed keywords

3' FLUOROTHYMIDINE F 18; CASPASE 3; DOXORUBICIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RESPONSE; EARLY DIAGNOSIS; ENZYME ACTIVATION; FEMALE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCID MOUSE; XENOTRANSPLANTATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; MUS;

EID: 53549089866     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-008-0162-3     Document Type: Article

References (36)

1. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
2. Lister TA, Crowther D, Sutcliffe SB et al (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636
3. Surbone A, Longo DL, DeVita VT Jr et al (1988) Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol 6:1832-1837
4. Jerusalem G, Beguin Y, Fassotte MF et al (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433
5. Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578
6. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA (2005) FDG PET in the evaluation of treatment for lymphoma: Clinical usefulness and pitfalls. Radiographics 25:191-207
7. Sandherr M, von Schilling C, Link T et al (2001) Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann Oncol 12:719-722
8. van Waarde A, Cobben DC, Suurmeijer AJ et al (2004) Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 45:695-700
9. Martiat P, Ferrant A, Labar D et al (1988) In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med 29:1633-1637
10. Shields AF, Mankoff DA, Link JM et al (1998) Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 39:1757-1762
11. Shields AF, Grierson JR, Dohmen BM et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334-1336
12. Barthel H, Perumal M, Latigo J et al (2005) The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 32:257-263
13. Kong XB, Zhu QY, Vidal PM et al (1992) Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 36:808-818
14. Sherley JL, Kelly TJ (1988) Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263:8350-8358
15. Eriksson S, Arner E, Spasokoukotskaja T et al (1994) Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv Enzyme Regul 34:13-25
16. Seitz U, Wagner M, Neumaier B et al (2002) Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F]fluoro-3′-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 29:1174-1181
17. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43:1210-1217
18. Lu L, Samuelsson L, Bergstrom M, Sato K, Fasth KJ, Langstrom B (2002) Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. J Nucl Med 43:1688-1698
19. Chen W, Cloughesy T, Kamdar N et al (2005) Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG. J Nucl Med 46:945-952
20. Cobben DC, Elsinga PH, Suurmeijer AJ et al (2004) Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′-deoxy-L-thymidine. Clin Cancer Res 10:1685-1690
21. Smyczek-Gargya B, Fersis N, Dittmann H et al (2004) PET with [18F]fluorothymidine for imaging of primary breast cancer: A pilot study. Eur J Nucl Med Mol Imaging 31:720-724
22. Wagner M, Seitz U, Buck A et al (2003) 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 63:2681-2687
23. Buck AK, Bommer M, Stilgenbauer S et al (2006) Molecular imaging of proliferation in malignant lymphoma. Cancer Res 66:11055-11061
24. Herrmann K, Wieder HA, Buck AK et al (2007) Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 13:3552-3558
25. Buck AK, Kratochwil C, Glatting G et al (2007) Early assessment of therapy response in malignant lymphoma with the thymidine analogue [(18)F]FLT. Eur J Nucl Med Mol Imaging 34:1775-1782
26. Momparler RL, Karon M, Siegel SE, Avila F (1976) Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 36:2891-2895
27. Di Bartolomeo S, Di Sano F, Piacentini M, Spinedi A (2000) Apoptosis induced by doxorubicin in neurotumor cells is divorced from drug effects on ceramide accumulation and may involve cell cycle-dependent caspase activation. J Neurochem 75:532-539
28. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW (2002) DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 303:124-131
29. Kano Y, Akutsu M, Tsunoda S et al (2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999-2007
30. Yang YJ, Ryu JS, Kim SY et al (2006) Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 33:412-419
31. Apisarnthanarax S, Alauddin MM, Mourtada F et al (2006) Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 12:4590-4597
32. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO (2005) Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 65:4202-4210
33. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: A pilot study in breast cancer patients with 3′-deoxy-3′-[(18)F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34:1339-1347
34. Troost EG, Vogel WV, Merkx MA et al (2007) 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 48:726-735
35. Wieder HA, Geinitz H, Rosenberg R et al (2007) PET imaging with [(18)F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 34:878-883
36. Kasper B, Egerer G, Gronkowski M et al (2007) Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk lymphoma 48:746-753